SHANGHAI, CHINA--(Marketwire - October 17, 2007) - Sinobiomed Inc. (“Sinobiomed”, or “the Company”) (OTCBB: SOBM) is pleased to update on the acquisition, by its 82% owned subsidiary, Shanghai Wanxing Bio-pharmaceuticals Co., Ltd. (“Shanghai Wanxing”), of Suzhou Boai Medical Development Co., Ltd. (“Suzhou Boai”).
